In recent years, the number of drug pipelines has steadily increased
Thyroid C-cell tumors The GLP-1 receptor agonist class carries a rodent-model thyroid C-cell tumor signal that anchors the FDA-required medullary thyroid carcinoma (MTC) and MEN-2 contraindications across approved GLP-1 products
Purification and biochemical properties of glutathione S-transferase from Lactuca sativa
GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications
4.10 Protein and Lean Mass Although not a micronutrient, protein intake is central to nutritional adequacy during GLP-1 therapy
Systemic side effects observed in retatrutide trials are broadly consistent with the GLP-1 receptor agonist class and include nausea, vomiting, diarrhoea, constipation, decreased appetite, and fatigue